The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Shares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of uncertainties ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...

Shares of Trump Media & Technology Group ( DJT ), which owns the Truth Social platform, were recently down 10% at about $36. They’ve mostly fallen since touching January highs above $40 and ...

During a fireside chat at the annual J.P. Morgan Healthcare Conference on January 13th, Mayo Clinic chief administrative ...

About two thirds of those at-risk for influenza are yet to be vaccinated this winter, according to Public Health Scotland.